Medipa s.r.o.

Brno 8 trials 7 recruiting

8 Registered trials

7 Currently recruiting

Organisation

Medipa s.r.o.

Location

Brno, Czechia

Identifier

ORG-100050643

Address

Slovakova 279/11, Veveri, 602 00, Czechia

Departments

N/A
NA
Private Medical Ambulance
Psychiatrická ambulance
Soukromá ambulance

Clinical trials at this site (8)

Search interface

Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting

2024-519836-18-00 treatment-resistant schizophrenia (TRS) 5 2025-12-16
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad… Recruiting

2025-521240-37-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-09-11
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious… Recruiting

2025-522347-18-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-11-26
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 Major Depressive Disorder 5 2025-09-26
A study to assess the efficacy and safety of ITI-1284 as monotherapy treatment in patients with Generalized Anxiety Disorder Recruiting

2024-516684-82-00 Generalized Anxiety Disorder 4 2025-07-21
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04